High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out
Jarvis, Joseph Na,b,c,d; Boulle, Andrewe; Loyse, Angelab; Bicanic, Tihanab; Rebe, Kevina,d; Williams, Anthonya; Harrison, Thomas Sb; Meintjes, Graemea,d,f
aInfectious Diseases Unit, GF Jooste Hospital, Manenberg, Cape Town, South Africa
bDepartment of Cellular and Molecular Medicine, St George's University of London, London, UK
cDesmond Tutu HIV Centre, South Africa
dDivision of Infectious Diseases and HIV Medicine, Department of Medicine, South Africa
eInfectious Diseases Epidemiology Unit, School of Public Health and Family Medicine, South Africa
fInstitute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Received 18 March, 2009
Accepted 19 March, 2009
Correspondence to Dr Joseph Nicholas Jarvis, GF Jooste Hospital, Duinefontein Road, Manenberg, 7764, South Africa. E-mail: email@example.com
Cryptococcosis is now the most common cause of adult meningitis in much of Southern and East Africa . Despite currently available antifungal therapies, acute mortality ranges from 30% to over 50% in published series [2,3]. The result is that cryptococcal infection accounts for 10–20% of mortality in HIV-infected cohorts from sub-Saharan Africa , and recently published estimates by Park et al.  place the overall toll at an estimated 504 000 deaths in sub-Saharan Africa annually.
As part of an ongoing programme of work aimed at improving management of cryptococcal meningitis, we have prospectively monitored the number of new India ink positive cases of cryptococcal meningitis diagnosed at GF Jooste Hospital, Cape Town, South Africa, for the last 6 years (2003–2008). This is a public sector adult hospital serving a population of 1.3 million (including a large part of Khayelitsha township, population 500 000, with an HIV antenatal seroprevalence of 32.7% in 2006 ). During this period, the area served by the hospital and referral patterns for patients have not changed. Antiretroviral therapy (ART) access has been substantially increased in the public sector clinics in the hospital's referral area from 660 adult patients on ART at the end of 2003 to 13 985 by the end of 2008, based on figures from the provincial reporting system described elsewhere . It is estimated that 60% of adults with new WHO stage IV HIV disease in this setting are now accessing ART . But, despite this increase in the proportion of eligible patients receiving ART, the absolute number of patients with advanced disease not accessing treatment has remained constant or increased in recent years due to the evolution of the epidemic . This is in keeping with our finding that there has been no reduction in the number of new India ink positive cases of cryptococcal meningitis presenting to our hospital over this period (Fig. 1).
There has been a major effort to expand access to ART throughout sub-Saharan Africa over recent years. However, despite implementation of successful treatment programmes, in many settings, the numbers of people progressing to advanced immunosuppression exceeds the capacity of ART programmes, and large numbers patients presenting to health services with advanced HIV and opportunistic infections die without accessing ART. The result is that the ‘treatment gap’ is not narrowed, and AIDS-related illness such as cryptococcal meningitis and the associated mortality are not reduced.
This is illustrated by the fact that, in the Western Cape Province, where GF Jooste hospital is located, the proportion of adult patients starting ART with CD4 cell counts below 50 cells/μl has fallen from 51.3% in 2001 to 21.5% in 2005 in line with increased access to care , whereas the absolute numbers of patients in this category has increased. Furthermore, unpublished aggregate data from the laboratory information system in the Province, further demonstrates that, irrespective of ART, the absolute numbers of all adult patients known to the healthcare system with CD4 cell counts below 100 cells/μl is increasing year-on-year (personal communication, Meg Osler, Provincial Government of Western Cape).
As these large numbers of patients with low CD4 cell counts not yet accessing ART remain at high risk of opportunistic infection, the burden of cryptococcal meningitis is likely to continue undiminished in many areas, despite increasing access to ART. These data reinforce the urgent need to improve the acute management of cryptococcal meningitis, and to facilitate earlier diagnosis and treatment, especially now that access to ART offers the possibility of a good long-term prognosis, provided that patients survive the acute cryptococcal infection . This needs to be specifically addressed as an integral part of the response to the HIV epidemic in Africa, along with earlier HIV diagnosis and access to ART.
J.N.J. and G.M. are supported by the Wellcome Trust, London, UK.
1. Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS 2007; 21:2119–2129.
2. Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker LG, Harrison T. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007; 45:76–80.
3. Kambugu A, Meya DB, Rhein J, O'Brien M, Janoff EN, Ronald AR, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008; 46:1694–1701.
4. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23:525–530.
5. Western Cape HIV Antenatal sero-prevalence survey in South Africa: 2007. Department of Health, South Africa. 2007.
6. Boulle A, Bock P, Osler M, Cohen K, Channing L, Hilderbrand K, et al. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 2008; 86:678–687.
7. Bicanic T, Wood R, Meintjes G, Rebe K, Brouwer A, Loyse A, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008; 47:123–130.
This article has been cited 5 time(s).
Brazilian Journal of Infectious DiseasesStrategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin AmericaBrazilian Journal of Infectious Diseases
Plos OneLong Term 5-Year Survival of Persons with Cryptococcal Meningitis or Asymptomatic Subclinical Antigenemia in UgandaPlos One
Clinical Infectious DiseasesEarly versus Delayed Initiation of Antiretroviral Therapy for Concurrent HIV Infection and Cryptococcal Meningitis in Sub-Saharan AfricaClinical Infectious Diseases
Samj South African Medical JournalPhased implementation of screening for cryptococcal disease in South AfricaSamj South African Medical Journal
BiomedicaCryptococcosis in Colombia: Results of the national surveillance program for the years 2006-2010Biomedica
© 2009 Lippincott Williams & Wilkins, Inc.